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Abstract
Juvenile idiopathic arthritis (JIA) is a disease characterized by
chronic joint inflammation, caused by a deregulated immune
response. In patients with JIA, heat shock proteins (HSPs) are
highly expressed in the synovial lining tissues of inflamed joints.
HSPs are endogenous proteins that are expressed upon cellular
stress and are able to modulate immune responses. In this review,
we concentrate on the role of HSPs, especially HSP60, in
modulating immune responses in both experimental and human
arthritis, with a focus on JIA. We will mainly discuss the tolerogenic
immune responses induced by HSPs, which could have a
beneficial effect in JIA. Overall, we will discuss the immune
modulatory capacity of HSPs, and the underlying mechanisms of
HSP60-mediated immune regulation in JIA, and how this can be
translated into therapy.
Introduction
Juvenile idiopathic arthritis (JIA) is an autoimmune disease of
unknown cause, characterized by a deregulated immune
response in synovial lining tissues of the joints, leading to
chronic arthritis in children. According to the latest classi-
fication provided by the International League of Associations
for Rheumatology, seven categories of JIA can be
distinguished, based on features present in the first 6 months
of disease [1]. All forms of JIA are extensively described in a
recent review by Ravelli and Martini [2]. Most of the literature
we discuss in this review involves two of the most common
forms: oligoarticular and polyarticular JIA. In the first
6 months, five or more joints are inflamed in polyarticular JIA,
whereas only up to four joints are inflamed in oligoarticular
JIA. Oligoarticular JIA can either be persistent or extended to
five or more joints. The fact that persistent oligoarticular JIA is
self-limiting, and in about half of all cases even self-remitting,
suggests an endogenous regulation of the immune response,
sometimes resulting in disease stabilization.
Heat shock proteins (HSPs) are endogenous proteins that
are expressed upon cellular stress and are able to modulate
immune responses. HSPs are highly present at sites of inflam-
mation, like the inflamed joints of JIA patients [3] (Figure 1a).
Previously, we reviewed the options for specific immuno-
therapy in JIA using immune modulatory fragments of proteins,
called peptides. This included some peptides derived from
HSPs: HSP60 and the bacterial HSP dnaJ. These peptides
were designed to be presented in major histocompatibility
complex (MHC) II molecules, and are recognized by T cells.
Thereby, these peptides enhance a specific immune res-
ponse. The mechanisms and advantages of specific immuno-
therapy in JIA, compared to currently used immunosup-
pressive therapies, were extensively discussed [4].
In this review, we focus on the immune regulatory mecha-
nisms of HSPs in arthritis, and, most importantly, JIA.
Although we discuss other members of the family of HSPs,
we concentrate on HSP60. First, we discuss the role of
HSP60 in immune regulation. Second, we continue with
immune regulation by HSP60 in experimental models of arthritis
and rheumatoid arthritis (RA) and then the role of HSP60 in JIA.
Last, we hypothesize on how the immune regulatory
properties of HSP60 can be translated into therapy.
Heat shock proteins
HSPs are evolutionarily highly conserved proteins, either
present constitutively, functioning as chaperones [5], or
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induced upon cell stress caused by, for instance, heat,
oxidative stress, and hypoxia [6,7]. Several HSPs have been
identified and, according to their size, organized into six
families: HSP100, HSP90, HSP70, HSP60, HSP40, and
HSP10.
In 1994 the ‘danger model’ was proposed by Polly Matzinger
[8]. According to this model, the reaction of the immune
response is not aimed towards ‘self’ or ‘non-self’, but towards
‘danger’. Immune cells can sense danger when tissues that
are stressed due to, for instance, infection release danger
signals, such as HSPs. Therefore, an immune reaction is only
elicited when necessary. As was discussed in a previous
review, these danger signals also play a role in chronic
inflammation [4]. As an example, in the inflamed joints of JIA
patients, HSPs are released from the injured or dying cells in
Figure 1
HSP60 specific T cells in the synovium of juvenile idiopathic arthritis (JIA) patients are IL-10-producing CD30+ regulatory T cell (Treg)-like cells.
(a) HSP60 (stained brown and marked by red arrows) is highly expressed in synovial lining membranes in the inflamed joints of JIA patients.
(b) HSP60 is released by the synovial tissues in the inflamed joint. In the synovial fluid, CD4+ T cells are present. T cells that react to the self-
HSP60 or HSP60 epitopes produce IL-10 [13,68] and express CD30. Presence of these HSP60-reactive T cells correlates with a mild disease
course [13]. Therefore, we hypothesize that these T cells could be CD25- and FOXP3-expressing naturally occurring Tregs [19], or IL-10-
producing T regulatory 1 cells. Altogether, HSP60 may induce Tregs in the joints of JIA patients and thereby regulate the inflammation of these JIA
patients, as is seen in oligoarticular JIA. HSP, heat shock protein.the synovial lining tissue and act as ‘danger signals’, alerting
the immune system [3,4]. This does not mean that HSPs
cause autoimmunity, but the increased expression and
release of HSPs can have a major impact on the resulting
immune response, as discussed below.
Indeed, different laboratories have documented variable
immune responses towards HSPs in humans. In vitro
experiments show that immune responses modulated by
HSPs can be pro-inflammatory, for instance, by eliciting an
interferon (IFN)γ response by T cells, or tumour necrosis
factor (TNF)α production by macrophages [9-11]. However,
HSPs can also induce an anti-inflammatory response, for
example, production of IL-10 [12,13]. HSPs are strong
immune modulators and are able to influence the impact and
direction of immune responses. In this review we will
elaborate on the tolerogenic (anti-inflammatory) response,
which, in different experimental settings, is attributed to an
induction of IL-10 production. In the past decade, IL-10
producing T cells became more and more of interest. These
cells belong to a population of T cells - called regulatory
T cells (Tregs) - that are key players in immune regulation
[14,15]. HSPs may be able to influence this population of
Tregs and thereby induce tolerogenic responses.
Heat shock protein-mediated induction of
tolerance: dependent on regulatory T cells?
Regulatory T cells
The involvement of HSPs in immune modulation, specifically
in immune suppression, and T cell reactivity towards HSPs
leading to suppression, raises the question of whether Tregs
are involved in this process.
In the past decade, Tregs have been extensively investigated
in several diseases. Their importance is clearly seen in
patients suffering from IPEX (immune dysregulation polyendo-
crinopathy, enteropathy, X chromosome-linked syndrome),
who lack functional Tregs due to a deficiency in FOXP3
(Forkhead box transcription factor P3) [15,16]. As a
consequence, these patients suffer from severe autoimmunity
and allergies. The relevance of Tregs in regulation of auto-
immunity has been confirmed by extensive research in several
mouse models for diabetes and RA in which the transfer of
Tregs to sick animals diminished disease [17,18]. Further-
more, the presence of Tregs correlated with a mild disease
course in JIA, implicating a role for Tregs in controlling
inflammation in JIA patients [19].
Subclasses of Tregs can be distinguished by their mecha-
nism of suppression and phenotype. In general, suppression
by Tregs is mediated by cell-cell contact and production of
suppressive cytokines. Naturally occurring Tregs (nTregs), for
instance, are present from birth and are distinguished by the
expression of IL-2 receptor α (IL-2Rα; also called CD25) and
FOXP3 [14]. T regulatory 1 (Tr1) cells, however, are induced
upon activation in peripheral tissues, and are characterized by
production of IL-10 and IFNγ [14]. It has been suggested that
the population of activation-induced Tregs is the most
important for immune regulation in humans [20,21]. In ex vivo
and in vitro studies in humans it is difficult to differentiate
between natural Tregs and induced Tregs. It is safe to
assume that all HSP60-induced Tregs are such activation-
induced Tregs; in the following, when using the term Tregs,
we are thus referring to these cells.
Regulatory T cell induction by HSP60
There is indeed evidence that HSPs can contribute to an
increase in Treg number and function. First of all, in animals
with adjuvant arthritis (AA), treatment with HSP60 peptide and
low dose anti-TNFα induced an increase in FOXP3-
expressing T cells, compared to treatment with high dose anti-
TNFα [22]. More in vitro data from patients with JIA suggest
that Tregs are influenced by HSP60. In these patients the
response of T cells to HSP60 [13], which correlated with a
beneficial outcome of disease, was characterized by a high
production of IL-10 and expression of the cell surface receptor
CD30. CD30 is a member of the TNF receptor (TNFR) family
and, in in vivo mouse experiments, was shown to be important
for Treg function [23-25]. CD30 expression on T cells
correlated with the production of T helper 2 cytokines and IL-
10, but also with the expression of CD25, which is a hallmark
of Tregs [23,24] (Figure 1b). These CD30 expressing T cells
could, therefore, represent a population of T cells that is able
to regulate the immune response. A role for CD30-expressing
CD4+ T cells in the regulation of human T helper 1 cell-driven
diseases, like RA, has also been suggested [26,27]. We
hypothesize that these CD4+CD30+ T cells could be
important in the regulation of inflammation in JIA joints as well
(Figure 1b). Future studies may elucidate whether, in inflamed
joints, CD30-positive cells represent just activated cells, or
cells with a possibly more regulatory phenotype.
Direct evidence showing an influence of HSPs on Tregs has
been provided by in vitro experiments in which HSP60 and
the HSP60 peptide p277 were able to enhance the regu-
latory function of the CD25-expressing Treg population from
human peripheral blood, probably by increasing Treg
migratory capacity [28,29]
HSP-mediated immune modulation: a
combination of innate and adaptive immunity
Thus, as discussed above, HSP60 and HSP60-derived
peptides seem to be able to enhance (Treg-mediated) immune
suppression. The next important step would be to unravel the
mechanism of Treg enhancement by HSP60. In this context,
it is important to mention that HSP60 can trigger both
adaptive and innate immune responses. HSP60 has been
suggested several times to be a ligand for the Toll-like
receptors (TLRs) 4 and 2 [11,30]. The TLRs belong to a
family of highly conserved receptors that recognize molecular
patterns of bacterial and viral origin, and form an important
part of the innate defence.
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takes place in bacteria, which means that there are always
bacterial components contaminating them. For instance,
microbial lipopolysaccharide, a ligand for TLR4, or microbial
proteins such as peptidoglycan, a ligand for TLR2, are often
detected in HSP preparations [31]. Therefore, to prevent
interference caused by bacterial products or HSPs, it is best
to focus on either highly purified HSPs, or on HSP peptides
that are synthesized de novo.
HSP peptides may be expected to induce a specific T cell-
mediated response as their selection is based on T cell
recognition. Interestingly, however, Cohen and co-workers [32]
discovered that some HSP-derived peptides can also induce
an innate immune response. They showed, as discussed
before, that HSP60 peptide p277, which was originally
identified as a peptide specifically recognized by T cell clones
[32], could enhance the population of Tregs. This was, how-
ever, mediated by TLR2 expressed on T cells [28]. Thus, appa-
rently similar to the whole protein, HSP60-derived peptides are
capable of activating both innate and adaptive immunity.
Dendritic cells: linking innate and adaptive immunity
The most direct link between the innate and adaptive immune
system is formed by the professional antigen presenting cells,
the dendritic cells (DCs). DCs express high levels of innate
receptors, such as TLRs. Stimulation of these TLRs causes
maturation of DCs. Conflicting data have been published
regarding the maturity of DCs and their influence on Tregs;
some data support that mature DCs are able to induce Tregs
[33], while other publications suggest that specifically
immature DCs can induce Tregs [34] (Figure 2a). The role of
TLRs expressed on the DCs in the induction of Tregs has
also been demonstrated to be controversial. On one hand,
TLR stimulation on DCs can enhance IL-10 production by
them, and thereby induction of Tregs (Figure 2a). On the
other hand, stimulation of TLRs on DCs can lead to inhibition
of Tregs and inflammation [35]. These data are mostly
obtained from experiments in mice and in vitro experiments
with human cells. Consistently, TLR agonists, tested in
clinical trials as a treatment for tumours, do not always induce
inflammation [35,36]. The direction of the immune response
may depend on the intracellular signalling pathways that are
induced [37]. Altogether, innate receptors can both directly
and indirectly (via DC modulation) influence adaptive
immunity and are able, in some cases, to contribute to the
induction of tolerance through Tregs (Figure 2a). It seems
likely that DCs, with their dual capacity to activate both
through the innate and adaptive receptors, could play an
essential role in the regulation of HSP60-mediated immunity.
This has, however, not yet been studied in humans.
Pathogen-associated molecular patterns enhance
HSP-mediated tolerance
In humans, memory T cells normally do not show a strong
immune response to self-HSP60, but only to bacterial
HSP60, whereas naïve T cells may readily respond to both
[38]. In addition, in cord blood, which comprises mainly naïve
T cells, responses to both human and bacterial HSP60 have
been detected [39]. Low T cell responses to self-HSP60 and
self-HSP60 peptides form an obstacle regarding their
therapeutic applicability. For an optimal therapeutic effect, it
seems logical to either enhance the self-HSP-mediated effect
or to use the bacterial homologues of the human HSP60
peptides in order to induce a strong memory T cell response.
Thus, enhancement of this response can be achieved by
combining the innate and adaptive immune system. The same
principle is used in vaccinations: an adjuvant, like bacterial
toxin, is used to elicit an immune response - in many cases via
TLRs - that is sufficient to achieve immunological memory
[40,41]. Furthermore, the innate immune response can be
used to steer the antigen-specific immune response; TLRs
can induce either a pro- or an anti- inflammatory reaction, as
discussed above.
Altogether, as for vaccination, the combination of enhancing
both adaptive and innate immunity may be attractive for
immune therapy of arthritis. As discussed before, HSP60 may
be able to do this on its own, as it can activate both the
innate and adaptive immune systems (Figure 2b). Bacterial
molecular patterns may enhance the effect of HSPs; for
instance, a complex of lipopolysaccharide and HSP60, via
TLR4 signalling in DCs, is able to enhance IL-12 production
by DCs and IFNγ production by T cells [9]. In these experi-
ments, the inflammatory response was enhanced via TLR4 on
DCs. In contrast, there is evidence that bacterial patterns
signalling via TLR2, TLR4 and TLR5 are able to enhance Treg
function as well [42-44]. However, in this setting, the
combination of bacterial patterns with HSPs or HSP peptides
has not been investigated.
We hypothesize that the immune response can be modulated
when T cell receptor (TCR) signalling is combined with TLR
signalling: a synergy of innate and adaptive immunity. We
propose that a combination of HSP peptides signalling
through the TCR and possibly also TLRs together with
pathogenic pattern signalling via TLRs could induce a
stronger tolerogenic response (Figure 2c). Since HSPs can
bind TLR2 and TLR4, their ligands, lipopolysaccharide and
peptidoglycan, would be interesting targets. However, to
achieve tolerance, the pathogenic patterns should be care-
fully tested in combination with HSP peptides to ensure that
the immune response is skewed towards tolerance, not
inflammation.
Heat shock proteins in arthritis
Several HSP families have been studied in relation to arthritis,
either in animal or in vitro JIA and RA models, and some were
even tested in vivo in clinical trials for RA. Although RA and
JIA differ in, for instance, disease presentation and age of
onset - RA onset occurs in adulthood, whereas JIA begins
Arthritis Research & Therapy    Vol 11 No 3 Vercoulen et al.
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caused by a deregulated immune system [2,45,46]. There-
fore, experimental findings in RA can also be useful for
developing potential treatments for JIA.
The tolerogenic effect of HSPs on immune responses was
discovered in experiments studying reactivity of T cells
towards bacterial and self-HSP in relation to arthritis. Several
members of the HSP family are immunogenic in both
experimental and human arthritis. Moreover, modulation of the
HSP-specific response can restore immune tolerance in
experimental arthritis; immunization with HSP10, HSP60,
HSP70 or HSP90 can suppress experimental arthritis in a rat
model of AA [47-50]. In humans, immune reactivity towards
several HSPs is found in both peripheral blood and synovial
fluid from patients with RA [51] and JIA [52,53]. In JIA, by far
the most data available are on immune reactivity to human
HSP60, which is discussed in depth below. Reactivity to
other HSPs is described as well; for example, human
homologues of peptides derived from the bacterial HSP dnaJ
can induce tolerogenic IL-10 responses in synovial fluid cells
of JIA patients [54].
In the context of RA, BiP, a member of the human HSP70
family, has drawn considerable attention. BiP is expressed in
the synovium of RA patients, and is recognized by T cells
from RA patients [55]. These BiP-reactive T cells showed a
low proliferative response and IFNγ production, but produced
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Figure 2
HSP60 uses both innate and adaptive immune pathways to enhance regulatory T cell (Treg) function. (a) HSP60 and HSP60-derived epitopes are
able to bind to Toll-like receptors (TLRs). By binding to TLRs present on dendritic cells (DCs), HSP60 can induce maturation of DCs or cytokine
production by them [9,11], which could possibly cause induction of Tregs. Both DCs and Tregs are able to produce IL-10, which inhibits activation
of effector T cells. To suppress the ongoing immune response, HSP60- induced Tregs could inhibit activation of effector T cells (Teffs) by cell-cell
contact and/or production of IL-10, or other cytokines, such as transforming growth factor β [14]. (b) Pan-HLA-DR (pan-DR) binding HSP60
epitopes are either presented to the Tregs in a major histocompatibility complex (MHC) II molecule by DCs, which could stimulate Tregs, or they
are able to bind to TLRs on the Tregs [28] and thereby enhance Treg function. We hypothesize that HSP60 and HSP60-derived epitopes can
enhance or induce Tregs by signalling through both the T cell receptor (TCR) and TLRs at the same time. HSP60 epitopes may bind directly to
TLRs on the T cells, or to TLRs on the DCs, which could indirectly enhance the immune response. (c) We hypothesize that a combination of a TCR
signal by a HSP60 pan-DR binding epitope and a TLR signal by a pathogenic pattern could enhance the HSP60-induced tolerogenic response,
causing a stronger and longer lasting immune regulatory effect.significant amounts of T helper 2 cytokines, such as IL-5 and
IL-10. Furthermore, an anti-inflammatory gene profile was
detected in monocytes after stimulation with BiP. These data
suggest an immune modulatory role for BiP in RA. In a
collagen-induced arthritis mouse model, similar results were
found and, importantly, BiP was able to both prevent and
treat arthritis [56]. Currently, the first clinical trials with BiP in
RA are being planned.
The first HSP that was tested in the clinic as a treatment for
RA is dnaJP1, a peptide derived from dnaJ. In a phase I
clinical trial in patients with early RA, mucosal administration
of dnaJP1 led to a shift in reactivity towards this peptide from
predominant pro-inflammatory to a more tolerogenic immune
response [52]. A recent placebo controlled phase II/III clinical
trial reported clinical improvement in RA patients after oral
treatment with dnaJP1 (EC Koffeman and S Albani, submitted
for publication). In this clinical trial, HSP peptides were
administered orally. Mucosal tissues are highly tolerant
tissues, as they need to be able to accept exogenous anti-
gens such as gut microbes and food. Therefore, encounters
of the mucosal immune system with antigens often leads to
‘oral tolerance’ [57,58]. Oral tolerance can be achieved by
induction of Tregs; for instance, mucosal administration of
antigen can lead to the induction of IL-10-producing Tr1
cells, which eventually leads to tolerance towards the antigen
[59]. This suggests that mucosal administration of antigens
like HSPs could be beneficial for the induction of a
tolerogenic response in arthritis. However, in both animal
models and a clinical trial in type 1 diabetes other ways of
HSP administration induced tolerance as well (reviewed by
van Eden and colleagues [60]).
So far, one HSP60 epitope has been tested in a human
autoimmune disease, diabetes. In a phase Ib/II clinical trial,
patients suffering from recent-onset type 1 diabetes were
treated by subcutaneous injections with epitope p277, the
same epitope that enhances Treg function in vitro [61].
Interestingly, these patients showed mainly IL-10 production
in response to the HSP60 peptide, and clinical improvement
was correlated with high IL-10 production before the start of
therapy [62]. Although this is not the subject of this review, it
underscores the potential of HSP60 peptides for treatment. It
is crucial, however, to better understand the mechanism of
HSP60-induced immune regulation before initiating clinical
trials in arthritis.
Thus, altogether, HSPs are immune modulators in both
experimental and human arthritis. Their common qualities are
their increased expression in inflamed tissue, such as synovial
tissue, and their ability to induce a tolerogenic response,
which may have therapeutic applicability. From here on, this
review concentrates on the most extensively studied HSP in
arthritis, HSP60. First, we discuss results obtained from
animal models, and then continue with the potential immune
modulatory role of HSP60 in JIA.
HSP60 in arthritis
HSP60 in experimental arthritis
The studies on HSP60 in human arthritis originate from
findings in the rat model of AA in the late 1980s [63]. AA, an
arthritis model with a close immunological and histopatho-
logical resemblance to RA and JIA, is induced by a single
injection with heat-killed Mycobacterium tuberculosis in
adjuvant.
First, it was found that T cell clone A2b, the arthritogenic
T cell clone in AA, was reactive to an epitope derived from
mycobacterial HSP65. Immunization with whole (myco-)
bacterial HSP65, however, not only failed to induce arthritis,
but also protected against the induction of AA [63].
Next, Anderton and colleagues [64] demonstrated that T cells
that were reactive towards bacterial HSP65 were responsible
for the observed protection against the development of
arthritis. Remarkably, protection from arthritis only occurred
when peptides of bacterial HSP65 with a high degree of
homology to self-HSP60 were used for immunization. This led
to the induction of cross-reactive T cells recognizing both
bacterial and human HSP [64].
This was, at the time, a stunning finding: it showed that,
even in an autoimmune model of arthritis, T cell reactivity to
self-proteins did not necessarily lead to autoimmune inflam-
mation. Moreover, T cell reactivity to self-HSP60 could lead
to a tolerogenic response, contributing to protection from
arthritis [64], as well as interference in ongoing arthritis
[12]. The next obvious question is how this immune
reactivity in experimental arthritis may relate to arthritis in
humans.
HSP60 in JIA
It has turned out that the results obtained in AA are remark-
ably complementary to observations in the human auto-
immune disease JIA. In inflamed joints from JIA patients, high
levels of self-HSP60 are expressed in the synovial mem-
branes [3] (Figure 1a). Furthermore, in these patients self-
HSP60 is recognized by T cells from the peripheral blood.
Interestingly, when T cell reactivity in synovial fluid from JIA
patients was analyzed, those patients suffering from the mild
and self-limiting oligoarticular form of JIA had an especially
clear T cell response towards self-HSP60, while polyarticular
patients did not [65]. This finding suggests a correlation
between disease severity and HSP60 reactivity of T cells in
these patients, in the sense that reactivity to self-HSP60 - like
in the model of AA - may be beneficial. This has been further
underscored in a prospective follow up study in new patients
with JIA that demonstrated that T cell reactivity to self-HSP60
at the onset of disease was associated with a benign disease
course [66]. Furthermore, self-HSP60 reactive T cells from
synovial fluid express CD30 and produce IL-10 [13]. As
discussed before, we suggest that these T cells are Tregs
(Figure 1b).
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Most of the discussed research has been performed using
whole HSPs. As HSPs are immune-modulators, it is important
to achieve the wished tolerogenic effect by selecting the
appropriate stimulus. This may depend on which part of the
protein is recognized by T cells and elicits the immune
response. Therefore, working with selected peptides derived
from the whole protein increases specificity, and it probably
reduces the chance of unwanted side effects. In experimental
models of arthritis, T cell peptides from HSP60 are capable
of having an effect with an efficacy that is similar to the whole
protein. The problem, however, lies in the identification of
such peptides in humans.
Humans, unlike the inbred animals used in experimental
models, have a very heterogenic HLA background. Different
HLA alleles have different binding affinities for peptides
(epitopes) that can fit in their HLA peptide binding site. As a
consequence, it is very difficult to determine which epitopes
of HSP60 can bind HLA from an individual patient. Thus,
predicting which epitopes are immunogenic in a heterogenic
disease such as JIA is extremely complicated. This problem
was overcome when, in collaboration with Alex Sette from the
La Jolla Institute of Allergy and Immunology, a PanDR binding
motif predicting computer algorithm that predicts binding to
all HLA-DR genotypes was used [67]. We succeeded in
selecting a set of HSP60-derived epitopes, both of human
and bacterial origin, that were immunogenic in JIA,
irrespective of the HLA background of the individual patients
[68].
In further studies, it has been shown that human HSP60-
derived T cell epitopes, which were selected for their multiple
MHC-genotype binding capacity, could both induce
inflammatory cytokines and also regulatory cytokines like
IL-10, depending on the specific epitope. Similar results have
been demonstrated for some selected homologous bacterial
HSP peptides. The induction of a tolerogenic response was
detected in patients with several MHC-genotypes, which
means that these peptides are able to induce beneficial
responses in a large population of patients, independent of
HLA background [68].
In the model of AA, the response to HSP60 has a dampening
effect on chronic inflammation. As was shown in vitro for the
HSP60 epitopes, this could also be the case for the res-
ponse to HSP60 and HSP60 epitopes in JIA patients. Thus,
HSP60 may contribute to the dampening of inflammation in
the joints of JIA patients with a remitting course of disease.
The identification of the HSP60 epitopes with a broad
recognition in patients with JIA is a major step forward in the
therapeutic application of HSP60 peptides in JIA.
Tregs in JIA joints: unable to suppress inflammation?
Many inflammatory cells are present in the joints of JIA
patients. Due to inflammation, a high amount of self-HSP60 is
released and, in addition, many FOXP3- and CD30-expres-
sing T cells are present in the synovial fluid (Y Vercoulen,
manuscript in preparation; Figure 1b) Somehow, the presence
of these T cells is not sufficient to completely diminish
inflammation. The ‘cytokine signature’ in synovial fluid from
oligoarticular and polyarticular JIA patients confirmed these
observations: IL-10 levels were higher in synovial fluid
compared to plasma from JIA patients. However, even higher
levels of pro-inflammatory cytokines were present in synovial
fluid - for instance, IFNγ and IL-6 [69].
The deficient immune regulation in the joints of JIA patients
could be attributed to the Tregs themselves: the amount of
Tregs may be insufficient, or the supposed Tregs may actually
be activated effector T cells that express FOXP3 transiently
[70]. However, in in vitro assays the FOXP3+ Treg, isolated
from the synovial fluid of JIA patients, can suppress activated
T cells (Y Vercoulen, manuscript in preparation). Furthermore,
the frequency of FOXP3- and CD30-expressing T cells is
higher than in peripheral blood, whereas the suppressive
capacity in vitro is comparable (Y Vercoulen, manuscript in
preparation). Therefore, it is more likely that the local inflam-
matory environment in the joint influences Treg functionality,
or makes activated T cells insusceptible to Treg-mediated
suppression. Obviously, this local highly inflammatory state
needs to be overcome before HSP60-mediated therapy,
which may target the Treg population, can be applied,.
Conclusion
In this review we give an overview of the relevance of HSP60,
and a few other HSPs, in JIA and immune modulation. We
discuss that HSPs in general can induce a tolerogenic immune
response, not only in vitro in human blood and synovial fluid
cells from inflamed joints and in vivo in experimental models,
but also in clinical trials in RA and type 1 diabetes. This
tolerogenic response is marked by the induction of IL-10, an
immune suppressive cytokine. Previous attempts at treatment
with recombinant IL-10 in clinical trials have not led to
improvements in RA patients [71]. It has been suggested that
IL-10, an immune suppressor, lacks efficacy [72]. We suggest
that administration of a single cytokine is not representative for
skewing of an immune response in which multiple cytokines are
involved. HSPs probably not only increase IL-10 production by
T cells, but also promote interactions of these cells with other
immune cells, eventually leading to a tolerogenic response.
Evidence for these suggestions has been provided in a recent
publication, in which transgenic IL-10-producing T cells,
specific for auto-antigen, were transferred into mice suffering
from proteoglycan-induced arthritis [73]. Although this is a very
artificial setting, these T cells reduced arthritis, which was
achieved by enhancing the endogenous tolerogenic response.
Another advantage of inducing antigen-specific, IL-10-
producing T cells is that they continue to produce IL-10 as long
as they are activated by their specific antigen [74]; when
inflammation decreases, less tissue proteins, such as HSPs,
are released, and the regulatory response decreases as well.
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Tregs [28]. The tolerogenic IL-10 responses that have been
found in several experimental settings indicate that HSP60
may be able to induce IL-10-producing Tr1 cells. In JIA
patients, HSP60 induces IL-10-producing CD4+ T cells,
which express CD30, and the presence of these cells
correlates with a mild course of disease [13]. Therefore, we
hypothesize that CD4+CD30+ T cells are able to regulate the
immune response in JIA. The suggested capacity of HSP60
to induce Tregs emphasizes the applicability of HSP60 (or
peptides derived from HSP60) for immune therapy in arthritis.
HSP60 peptides influence Tregs via the TCR [68], or via
TLRs [28], which are present on both T cells and antigen-
presenting cells such as DCs. This opens an intriguing
possibility for immune therapy; to use one single peptide that
may trigger antigen-specific T cells and may enhance this
response by inducing innate immunity through TLR triggering
at the same time.
Preliminary data suggest that a combination of both TCR and
TLR activation causes induction of Tregs (De Kleer et al.,
manuscript in preparation). We hypothesize that Treg
induction could even be enhanced by further augmenting
innate immunity through TLR triggering by, for instance,
pathogen-associated molecular patterns.
In humans, peripheral induction of Tregs is thought to be of
high importance in the regulation of inflammation [20,21].
However, in JIA joints, many CD4+CD30+FOXP3+ T cells are
present, which are functional Tregs in a neutral environment
in vitro (Y Vercoulen, manuscript in preparation). It is likely
that the chronic inflammatory environment in the joints either
causes local dysfunction of Tregs or makes activated cells
insusceptible to Treg suppression. Therefore, suppression of
inflammation is necessary before Treg targeted therapy can
be applied.
Towards therapy
Thus, to create a therapeutic window for HSPs, it may be
important to first dampen chronic inflammation in the joints -
for instance, by using anti-TNFα therapy [22]. Second, the
combination of HSPs and modulators of innate immunity,
such as pathogenic patterns, should be investigated more
thoroughly. The combination of these two immune modulators
may induce a stronger and longer lasting effect on the
immune system by HSPs. However, both pathogenic patterns
and HSPs can induce either tolerance or inflammation.
Therefore, it is important to carefully select HSP epitopes and
pathogenic patterns to ensure that they enhance only the
tolerogenic effect and do not tip the delicate immune balance
towards inflammation.
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